Drug intelligence / Profile preview

SYS6057

Development stage: Unknown
Lead developer: CSPC Pharmaceutical Group
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SYS6057 is a recombinant protein vaccine candidate developed by CSPC Pharmaceutical Group for the prevention of Respiratory Syncytial Virus (RSV) infection. Developed by the group's R&D subsidiary, ZhongQi Pharmaceutical Technology, the vaccine utilizes recombinant technology to express viral antigens intended to stimulate a protective immune response. In August 2023, the company received approval from the China National Medical Products Administration (NMPA) to initiate clinical trials. The program aims to address the significant disease burden of RSV in vulnerable populations, including infants and older adults.

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on SYS6057.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYS6057.

Explore the full profile